Proteinuria and exposure to eculizumab in atypical hemolytic uremic syndrome
M Ter Avest, H Steenbreker… - Clinical Journal of the …, 2023 - journals.lww.com
Background Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic
uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may …
uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may …
[HTML][HTML] Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation
C Duineveld, RN Bouwmeester, KL Wijnsma… - Kidney International …, 2023 - Elsevier
Introduction Since 2016, kidney transplantation in patients with atypical hemolytic uremic
syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis …
syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis …
Can complement activation be the missing link in antiphospholipid syndrome?
V Venturelli, B Maranini, I Tohidi-Esfahani… - …, 2024 - academic.oup.com
APS is an autoimmune disorder with life-threatening complications that, despite therapeutic
advantages, remains associated with thrombotic recurrences and treatment failure. The role …
advantages, remains associated with thrombotic recurrences and treatment failure. The role …
Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics
O Le Tilly, P Gatault, S Semlali… - British Journal of …, 2024 - Wiley Online Library
Aims Eculizumab is a monoclonal antibody targeting complement protein C5 used in renal
diseases. As recommended dosing regimen leads to unnecessarily high concentrations in …
diseases. As recommended dosing regimen leads to unnecessarily high concentrations in …
[HTML][HTML] [Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy
AP Parra, N Ramos, J Perurena-Prieto… - Farmacia …, 2024 - Elsevier
Objective The objective of the study was to analyze and describe the concentrations of
eculizumab and the complement blockade in patients with atypical hemolytic uremic …
eculizumab and the complement blockade in patients with atypical hemolytic uremic …
[HTML][HTML] Farmacocinética de eculizumab en pacientes adultos y pediátricos con síndrome hemolítico urémico atípico y glomerulopatía C3
AP Parra, N Ramos, J Perurena-Prieto… - Farmacia …, 2024 - Elsevier
Objetivo analizar y describir las concentraciones de eculizumab y el bloqueo del
complemento en los pacientes con síndrome hemolítico urémico atípico (SHUa) y …
complemento en los pacientes con síndrome hemolítico urémico atípico (SHUa) y …
Pacjent z nocną napadową hemoglobinurią w codziennej praktyce lekarskiej: od lekarza podstawowej opieki zdrowotnej do hematologa–opis przypadku
J Kozińska - Medycyna Faktów, 2023 - journalsmededu.pl
Nocna napadowa hemoglobinuria jest nabytą niedokrwistością hemolityczną
charakteryzującą się triadą objawów: hemolizą wewnątrznaczyniową, pancytopenią i …
charakteryzującą się triadą objawów: hemolizą wewnątrznaczyniową, pancytopenią i …